Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Revised: September 20, 2026
Accepted: October 16, 2026
Published online: November 24, 2026
Processing time: 81 Days and 1.4 Hours
Recent progress in treatments has dramatically improved the outcomes of co
Core Tip: The majority of patients with colorectal cancer (CRC) undergo chemotherapy and/or chemoradiotherapy (CRT) in various settings. The safety and efficacy of these treatments may be affected by factors such as sex, age, and body compositions. Furthermore, these factors may be interrelated in the context of chemotherapy and CRT. It is crucial to understand the impact of the three S's (sex, seniors, and sarcopenia) on CRC treatment in clinical practice.
- Citation: Nozawa H, Murono K, Emoto S, Ishihara S. Three S’s (sex, seniors, and sarcopenia) matter during chemotherapy for colorectal cancer. World J Clin Oncol 2026; 17(11): 127405
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/127405.htm
- DOI: https://dx.doi.org/10.5306/wjco.127405
Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, and exhibits the second highest mortality rate[1-3]. The prognosis of patients with CRC is usually determined by tumor stage. Stage II and III diseases that are high-risk are indications for six months of adjuvant doublet chemotherapy based on 5-fluorouracil (5-FU) and oxaliplatin after CRC resection[4-8]. The results of the IDEA Collaboration Study suggest an alternative administration of a three-month adjuvant CAPOX therapy (oral prodrug of 5-FU, capecitabine, plus oxaliplatin) for low-risk stage III colon cancer[9]. While systemic therapy is the standard treatment for metastatic CRC (mCRC)[6-8,10], patients with resectable stage IV CRC may also benefit from adjuvant chemotherapy[6]. Additionally, patients with locally advanced rectal cancer are currently candidates for neoadjuvant chemoradiotherapy (CRT)[5,8]. The state-of-the-art treatment is total neoadjuvant therapy (TNT), which is a combination of CRT and chemotherapy before rectal surgery. TNT could increase the rate of pathological or clinical complete responses (cCR), enabling non-operative management for some patients with rectal cancer[11]. Therefore, many patients with CRC undergo oral or infusional chemotherapy, either alone or in combination with radiotherapy, to improve prognosis, although the timing and duration of treatment depend on tumor location and stage.
A large percentage of patients who undergo chemotherapy or CRT face severe toxicity[12,13]. It is well recognized that tolerance to chemotherapy or CRT depends on sex and age. Importantly, these unchangeable variables are often associated with sarcopenia, which is also associated with tolerance of these therapies. Since sarcopenia is a significant factor in chemotherapy toxicity, it may also affect survival. Conversely, chemotherapy can directly and indirectly cause sarcopenia to deteriorate in cancer patients (Figure 1)[14]. Moreover, deteriorated health conditions, including cancer progression can cause secondary sarcopenia[15]. Therefore, it is crucial to understand the relationships of these mutual relationships in order to administer chemotherapy and CRT safely and effectively.
In this review, we searched the PubMed database using the following terms: “colon cancer”, “colorectal cancer”, “rectal cancer”, “chemotherapy”, “systemic therapy”, “radiotherapy”, “chemoradiotherapy”, “immunotherapy”, “immune checkpoint inhibitor”, “targeted therapy”, “adverse event”, “efficacy”, ”response”, “survival”, ”complication”, or “epidermiology”, as well as keywords related to the topics listed below: “sex”, “sex difference”, “male”, “female”, “seniors”, “age”, “aged”, “elderly”, “older”, “geriatric”, “sarcopenia”, “sarcopenic”, “frail”, “frailty”, “muscle mass”, “muscle loss”, “muscle index”, “body mass”, “body weight”, “body mass”, “adiposity”, “myosteatosis”, or “body com
Primary sarcopenia is part of the normal aging process, which involves a progressive reduction in muscle mass starting from the age of 20s to 40s[16,17]. The percentage in healthy individuals rises from 9% at 45 years of age to 64% at ages greater than 85 years[18].
The prevalence of sarcopenia varies depending on the country, ethnicity, and population (e.g., community-dwelling, nursing home, or hospitalized). It also depends on the method used to determine cutoff values and the definition of sarcopenia itself. Papadopoulou et al[19] reported that sarcopenia was found in 51% of men and 31% of women among older adults in nursing homes, whereas it was found to affect 23% and 24% of men and women, respectively, among hospitalized individuals.
A longitudinal study by Gallagher et al[20] observed a greater decrease in skeletal muscle mass with age in African-Americans than in Caucasians. Sarcopenia appears to be more common in individuals from non-Asian countries than in Asian individuals. It can be explained by several possibilities. The cutoff points for low skeletal muscle mass in the Asian populations mostly defined according to young reference adults are lower than those for the non-Asian individuals in both sexes[21,22]. Second, Asians, especially women, are known to have higher central adiposity than Caucasians[23]. Therefore, muscle index adjusted by height may underestimate the prevalence of sarcopenia with low muscle mass (sarcopenic obesity).
Regarding sex disparity, a review of people aged 75 years in Western countries found that muscle mass was lost at a rate of 0.80%-0.98% per year in men and 0.64%-0.70% per year in women[24]. Muscle strength was reduced more rapidly at a rate of 3%-4% per year in men and 2.5%-3% per year in women[24]. Asian men also tend to lose muscle mass gradually with aging, but not Asian women in cross-sectional and longitudinal studies[25-27]. Although men lose more muscle with age, women seem to suffer more from the consequences of lean tissue loss, probably due to their lower initial mass and greater longevity[28].
CRC is caused by multiple risk factors such as smoking, drinking, dietary habits, and obesity, all of which are associated with sex[29-32]. Some tumor-suppressor genes are located on the X chromosome. Because women have two copies of the X chromosome, they are likely to retain functional copies even after mutations occur[33]. Men have a higher incidence and mortality rate of predominantly left-sided cancer. Women are more frequently diagnosed with right-sided cancer, which is more aggressive and less responsive to conventional chemotherapy[34]. In addition to these sex differences in colorectal carcinogenesis and tumor phenotypes, women have stronger innate and adaptive immune responses, with higher numbers of CD4+ and CD8+ T cells and lower numbers of regulatory T cells than men. Women are also more likely to retain a T cell population that decreases significantly in men over the age of 65[35].
The pharmacokinetics of 5-FU differ between the sexes. Plasma clearance of 5-FU is lower and the area under the plasma concentration-time curve is higher in women than in men[36]. Because of the higher plasma level of 5-FU, women are more likely to experience various adverse events and severe toxicities, including hand-foot syndrome and hematological and gastrointestinal symptoms, in response to 5-FU-based chemotherapy[37-40]. A past review described no significant differences in the clearance of oxaliplatin between men and women[41]. Several studies pointed out higher irinotecan exposure in women, which could be partially explained by decreased clearance of SN-38, while others found no such sex-related differences[42,43].
In palliative settings, doublet or triplet regimens plus targeted antibodies are often used. In the PanaMa study, a higher rate of nausea, diarrhea, and stomatitis of any grade was reported in female patients who received 5-FU/leucovorin (LV) with or without anti-epidermal growth factor receptor (EGFR) antibodies, panitumumab[44]. A subgroup analysis of the Valentino study revealed significantly higher toxicity without altering the survival outcome of female patients with RAS-wild type mCRC who received single-agent panitumumab or panitumumab plus 5-FU/LV as maintenance therapy following a first-line panitumumab plus doublet FOLFOX-4 regimen[45]. In a meta-analysis of first-line oxaliplatin-based doublet chemotherapy with or without targeted therapy, women with mCRC experienced a higher incidence of he
There are several reports on sex disparities in adverse events associated with molecular targeting drugs. In the FIRE-3 trial, which was a comparison of first-line FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in patients with RAS wild-type mCRC, a statistically significant discrepancy in the incidence of adverse events between sexes was not observed in either arm[53]. On the other hand, it has been demonstrated that other targeted drugs carry a higher risk of severe adverse events in women[54]. For instance, regorafenib, a multi-kinase inhibitor used for refractory mCRC, has been shown to induce a higher frequency of toxicities, including anorexia, fatigue, hypertension, and skin rash, in women[55,56]. Trastuzumab deruxtecan (T-Dxd) has shown significant anti-tumor activity in a variety of HER2-positive solid tumors[57]. In the DESTINY-CRC01 study for refractory mCRC, T-Dxd demonstrated a comparable response rate (RR) and PFS, with no mention of differences in safety profiles between sexes[58]. Recently, several molecules targeting KRAS mutations have been developed for solid tumors, including CRC. There is no report on the impact of sex on the outcomes of KRAS G12C inhibitors in CRC, although a pharmacokinetics study estimated a higher exposure to sotorasib in women, even when administered at the same dose[59].
Microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) cancer accounts for 3.5% to 6.5% of CRC. For cases of metastatic disease, patients are recommended to receive immune checkpoint inhibitors (ICIs)[7,8,10]. Patients treated with ICIs often develop immune-related adverse events (irAEs) that strongly resemble autoimmune diseases. A combined analysis of SWOG phase II and III RCTs for various types of malignancies revealed that ICIs caused severe symptomatic irAEs in women more markedly than in men[54]. The result may be associated with an increased prevalence of autoimmune diseases[60] or a stronger immune response in women as described above[35]. In contrast, recent meta-analyses have shown that ICIs provide comparable OS in both men and women[61-63].
In general, women with locally advanced rectal cancer who receive neoadjuvant long-course CRT (typically 50.4-54 Gy plus 5-FU) experience a higher severity of hematologic adverse events, as well as perianal dermatitis and diarrhea, than men[64-66]. Additionally, women with rectal cancer are more likely to experience discontinuation or interruption of CRT[67,68]. A study using multi-omics data revealed sex-biased bacterial species, microbiota-derived functional profiles, and metabolites in the gut, which may explain the difference in toxicity between sexes[69]. In most reports on neoadjuvant long-course CRT for rectal cancer, histopathological outcome, such as tumor regression grade and pathological complete response (pCR), did not differ by sex in Caucasian and Asian populations[70-73]. A few exceptions include a Croatian study that reported a higher pCR rate in men who received a lower dose (45 Gy) of radiation as part of neoadjuvant CRT[74]. In contrast, a Canadian study reported that the adjusted odds ratio for pCR after long-course CRT was 1.41 (95% confidence interval: 1.01-1.96; P = 0.041). However, the study may be subject to selection bias, given that the database contains more patients who received short-course radiotherapy than long-course CRT[75].
Regarding the outcomes in TNT, a secondary analysis of the phase II OPRA trial revealed that sex was not associated with clinical tumor response grades[76].
The postoperative survivals after CRT for rectal cancer can be influenced by surgical difficulty, which varies according to the patient's sex and body composition. A Chinese study reported that male sex is a predictor of poor OS after neoadjuvant CRT and surgery for rectal cancer[77]. In contrast, a Korean study found no association between sex and OS[78].
In the adjuvant setting, women with CRC exhibited higher 5-FU dose-limiting toxicity (DLT) compared to men. The higher frequencies of common toxicities and the need for dose reduction of adjuvant capecitabine may result in lower relative dose intensity in female patients[79]. According to an ACCENT database study, there was a higher incidence of grade 3 or higher non-hematological toxicities in female patients who received adjuvant 5-FU with or without oxaliplatin for CRC[80]. Our previous research indicates that being female is an independent risk factor for developing early DLT in patients undergoing adjuvant CAPOX therapy[81]. A pooled analysis of four RCTs on adjuvant 5-FU monotherapy conducted in Japan (JCOG2310A) also found a higher incidence of grade 3-4 adverse events in women. However, being female was a favorable prognostic factor for OS (hazard ratio 0.80) and recurrence-free survival (RFS, hazard ratio 0.73) in multivariable analyses in this study[82]. An analysis of patients with stage III colon cancer from the CALGB/SWOG 80702 (Alliance) study revealed that female patients exhibited lower adjuvant FOLFOX completion rates and a higher incidence of adverse events. Similar to the results of the JCOG2310A study, they demonstrated superior RFS, disease-free survival (DFS), and OS when compared to male patients[83]. It is important to note that the differences in survival rates may be due to a combination of factors, such as tumor biology and the fact that women have a longer lifespan, rather than differences in sensitivity to adjuvant chemotherapy.
In general, the pharmacodynamics and pharmacokinetics of chemotherapeutic drugs can undergo changes with age, which may result in increased toxicity from chemotherapy[84,85]. For instance, irinotecan clearance is significantly reduced by age[86], which may explain the increased risk of diarrhea or neutropenia caused by irinotecan in the older adults[49]. The area under the curve of 5-FU also increases with age; however, the pharmacokinetics of oxaliplatin are not affected by age[41,86].
Furthermore, the occurrence of treatment toxicity can be amplified by the presence of multiple comorbidities, physical disability, and/or polypharmacy[87]. The senior population is a highly heterogeneous group, given the wide range of severity levels of geriatric conditions among individuals. Therefore, doctors should classify patients with CRC as follows: Fit, vulnerable (medium fit), or frail (unfit) for chemotherapy and other treatment modalities[6,10]. A geriatric assessment can be performed using screening tools such as the G-8 followed by the Comprehensive Geriatric Assessment (CGA) for the above classifications[88-91]. If aged patients are undertreated just because they are old, it may result in the ineffectiveness of cancer therapy for fit patients[92,93]. Conversely, studies have shown that over-treatment of patients deemed unfit can lead to an increased occurrence of grade 3-4 toxicities when compared to patients receiving treatment tailored to their individual fragility[93]. The GAIN trial evaluated multidisciplinary intervention based on geriatric assessment (self-reported measures of functional status, comorbidity, psychological state, social activity/support, nutritional status physician-rated Karnofsky Performance Status, Timed Up and Go test, Blessed Orientation-Memory-Concentration test, body weight and height, and unintentional weight) in patients aged over 65 years who are receiving chemotherapy for various types of gastrointestinal or other cancers; the intervention resulted in a 10% reduction in grade 3-5 toxicity and a 15% increase in the treatment completion rate compared to standard care[94]. The GAP70+ trial demonstrated that a management approach involving geriatric assessments with similar patient-reported and objective measures to those in the GAIN trial reduced grade 3-5 toxic effects by 20% and DLT by 9% in patients aged over 70 years with incurable solid tumors or lymphoma[95].
According to the latest guidelines, fit aged patients can receive treatment strategies comparable to those applied to younger patients[5,96]. The benefits of 5-FU are comparable between older and younger patients with mCRC, in terms of RR and OS[97-99]. In contrast, the benefits of oxaliplatin- or irinotecan-based combinations in older adults remain a subject of debate[99,100]. Several RCTs and a meta-analysis have shown that doublet chemotherapy increases the RR, but improvement in PFS or OS has not been observed uniformly in aged patients with mCRC[101-103].
The administration of additional anti-VEGF antibodies, such as bevacizumab, in conjunction with cytotoxic drugs has been demonstrated to yield a positive effect on PFS in senior patients. However, the impact on OS is not universally positive[104-107]. The BRiTE observational study of bevacizumab combined with first-line chemotherapy showed similar PFS rates among all age subgroups. However, the OS decreased with age in the study[108]. With respect to the safety of bevacizumab, a higher incidence of arterial thromboembolic adverse events was observed in aged patients in the BRiTE study and in a pooled analysis of RCTs on bevacizumab plus chemotherapy[108,109]. In the findings of the aforementioned TRIBE and TRIBE2 trials, a considerable proportion of aged patients receiving first-line triplet or doublet combinations with bevacizumab experienced elevated rates of grade 3-4 toxicities, including diarrhea and febrile neutropenia (aged patients: 73% vs young patients: 60%, P < 0.01)[47].
Other drugs that target VEGF or its receptors include ramucirumab, aflibercept, and fruquintinib. A subgroup analysis of the phase III RAISE study revealed that the toxicity profile and survival benefit of ramucirumab remained consistent across two distinct age groups, with a cutoff age of 65 years[110]. A post-hoc analysis of the VELOUR study, which investigated the use of aflibercept in combination with second-line FOLFIRI for mCRC, revealed no significant differences in OS between patients aged ≥ 65 years and those aged < 65 years. However, the study noted that older adults experienced a higher incidence of adverse effects, including diarrhea, dehydration, and weight loss[111]. A subgroup analysis of the FRESCO trial revealed that the frequency of fruquintinib-related adverse events was consistent across all subgroups, including age and sex[112]. The FRESCO-2 study revealed that fruquintinib demonstrated survival benefits in terms of PFS and OS for patients aged ≥ 65 years, as well as for those < 65 years[113].
Fit aged patients with RAS wild-type CRC can receive doublet chemotherapy plus anti-EGFR antibodies. This treatment has comparable toxicity and similar benefits in terms of RR and PFS to those observed in younger patients[114,115]. T-Dxd demonstrated comparable RR and PFS between patients aged ≥ 65 years and those < 65 years in the DESTINY-CRC01 study for mCRC[58]. A pooled analysis of nine studies across various malignancies, including CRC, revealed that younger patients (age < 65 years) exhibited an elevated risk of drug-related interstitial lung disease/pneumonitis when treated with T-Dxd[116].
In the case of vulnerable aged patients, a reduced dose of doublet chemotherapy could be administered. In a phase II RCT comparing reduced-dose doublet therapy of S-1 and oxaliplatin (SOX) with full-dose S-1 monotherapy for patients aged ≥ 70 years with mCRC who were not candidates for full-dose SOX, the former combination regimen was more effective and resulted in less toxicity[117]. Moreover, the addition of anti-EGFR antibodies to doublet chemotherapy has shown promising results in many phase II trials, offering the potential for enhanced survival and improved quality of life (QoL) for vulnerable patients with mCRC[118-121]. However, it is important to note that vulnerable patients are more likely to experience a decline in performance status and unplanned hospitalizations during chemotherapy compared to fit patients[122].
A post-hoc analysis of the phase III RECOURSE study for refractory mCRC revealed that trifluridine/tipiracil demonstrated comparable benefits in terms of PFS and OS for older and younger patients[123]. Another study revealed that there was no statistically significant difference in the safety profile of trifluridine/tipiracil between older and younger patients[124]. A post-hoc analysis of the CORRECT trial showed no statistically significant differences in the safety or efficacy of regorafenib between patients ≥ 65 years vs those < 65 years[125]. Similarly, the CONSIGN trial revealed that there were no observed differences in the safety and efficacy profile of regorafenib based on age[126].
In the pivotal phase III RCT of first-line ICI, KEYNOTE-177 study, patients with MSI-H/dMMR mCRC were ran
The majority of milestone RCTs that have demonstrated the benefits of neoadjuvant CRT for rectal cancer excluded patients over the age of 75[129-131]. This has led to ongoing concerns regarding the safety and efficacy of CRT in older adults. Fortunately, like systemic therapy described above, neoadjuvant CRT seems to be safely administered to selected aged patients with locally advanced low rectal cancer in both Western and Asian countries[132-136]. Several study groups in Japan have compared neoadjuvant CRT for rectal cancer in older patients (aged ≥ 75 years or 80 years) and younger patients (aged < 75 years or 80 years). The results indicate that there are no differences in CRT-related toxicity, pathological response, and survival outcomes between the two age groups[137,138], although frequent chemotherapy dose reductions may be necessary for older Japanese adults[138]. Another Japanese study compared the safety and surgical outcomes of older (≥ 65 years) and younger patients (< 65 years) receiving long-course CRT for rectal cancer; anorexia was more frequently observed in older adults during CRT, while surgical complications, DFS, and OS were comparable between the age groups[139].
In addition to long-course CRT, there are other neoadjuvant treatment options for advanced rectal cancer. A phase III RCT demonstrated that a short course of radiotherapy (25 Gy/5 fractions over one week) followed by delayed surgery may serve as a preferred treatment option for older adults (≥ 75 years) because of fewer serious adverse events before surgery and less deterioration of daily activities after surgery[140].
Another option that may be suitable for vulnerable seniors diagnosed with rectal cancer is brachytherapy. The Phase I HERBERT study on external-beam radiation therapy (39 Gy/13 fractions) followed by three weekly image-guidance high-dose-rate brachytherapy (5-7 Gy/fraction) demonstrated that four (67%) of six patients (median age: 84 years) achieved cCR or near complete response without regrowth[141]. The OPERA trial demonstrated that a contact brachytherapy boost (90 Gy/3 fractions) in combination with CRT significantly enhanced the 3-year organ preservation rate in patients with cT2-3 rectal cancer (median age: 69 years)[142]. As stated by GEC-ESTRO-ACROP, contact brachytherapy shows great promise as a treatment for rectal cancer in both definitive and palliative settings[143].
In the context of TNT, Bananzadeh et al[144] examined the outcomes of sequential neoadjuvant chemotherapy and short-course radiation therapy in patients of varying age groups. The study concluded that the pCR rate and treatment-related toxicity were comparable between the older and younger age groups.
From an epidemiological perspective, it is noteworthy that right-sidedness, BRAF V600E mutation, and MSI-H are overlapping characteristics of aged patients with CRC. BRAF mutations are associated with a high risk of recurrence in stage II and stage III CRC cases[145]. MSI-H has been shown to be associated with a favorable prognosis[146,147]. However, the efficacy of adjuvant 5-FU was not observed in high-risk stage II and stage III CRC with MSI-H[148,149].
Antonio et al[150] prospectively investigated the relationship between frailty, as determined by geriatric assessment, and the cause of death in patients aged ≥ 75 years with high-risk stage II and stage III CRC; the study revealed that the risk of cancer-related mortality was comparable between fit and medium fit patients, whereas unfit older adults exhibited a significantly higher risk of mortality from causes other than cancer. They concluded that the most appropriate therapeutic decision was to withhold adjuvant treatment from unfit patients with localized CRC[150].
The majority of RCTs on adjuvant 5-FU monotherapy (X-ACT, JCOG0205, and ACTS-CC) demonstrated similar survival benefits for 5-FU in older and younger patients (cutoff: 70 years)[151-153] except for the QUASAR study[154]. Regarding adjuvant doublet therapy, most older RCTs (MOSAIC, NSABP C-07, and XELOXA) did not demonstrate an improvement in either DFS or OS in patients aged > 70 years by oxaliplatin[12,155-157]. Pooled analyses of RCTs showed that the addition of oxaliplatin provided limited benefits in terms of DFS and OS in patients aged > 70 years[158,159]. However, a recent analysis covering newer studies showed definite survival benefits in older adults (> 65 years) from doublet therapy[160]. A study using a population-based cancer registry database in Japan showed that monotherapy or doublet chemotherapy did not reduce all-cause mortality in patients aged ≥ 75 years with stage III colon cancer, after adjusting for other clinical parameters[161]. On the other hand, another cancer registry-based study in the United States found a survival benefit from adjuvant chemotherapy in patients in the same setting, but denied any benefit from oxaliplatin[162]. In real-world practice, Shiraishi et al[163] reported that, unlike younger patients, patients aged ≥ 70 years did not benefit from adjuvant chemotherapy. Whilst, Yamano et al[164] found that adjuvant 5-FU-based monotherapy prolonged OS in stage III CRC patients aged > 75 years. Our group also demonstrated that adjuvant chemotherapy was associated with improved cancer-specific survival (CSS) and OS in aged patients (≥ 70 years) with stage III CRC, even though they were less likely to be treated with oxaliplatin and received lower chemotherapy doses than younger patients[165]. Overall, adjuvant 5-FU may contribute to prolonged OS in aged patients with CRC. Conversely, the survival benefits of oxaliplatin use have not been established for older adults, particularly those aged ≥ 75 years. However, the OS improvements were reported in newer trials of doublet chemotherapy compared to older ones in aged patients. It may be partly explained by a recent trend of high activity that does not align with one's chronological age, and/or by the advances in multifaceted supportive care, including increased medical and surgical support, allowing older adults to benefit more.
Regarding the toxicity of adjuvant 5-FU monotherapy, a single-institute study found no increased toxicity in patients aged 65-75 compared to younger patients[166]. The toxicity of adjuvant doublet therapy has produced mixed results. A retrospective study conducted by a single institute in Denmark showed no age-dependent differences in grade 3-5 toxicity, DFS, or CSS[167]. Conversely, a population-based study of Dutch patients over 70 years of age revealed increased toxicity with oxaliplatin-based chemotherapy, which significantly impacted cumulative doses received and completion of all planned cycles. This resulted in reduced benefits from adding oxaliplatin to treatment regimens for older adults[168]. The phase III RCT, ADAGE-PRODIGE 34 study compared four treatment arms in patients aged > 70 years after the resection of stage III colon cancer: Oxaliplatin plus 5-FU vs 5-FU alone in fit patients (Group 1), and 5-FU vs observation in frail patients (Group 2)[169]. In this trial, grade 3-5 toxicities occurred more frequently in patients treated with the doublet regimen in Group 1 or with 5-FU in Group 2 than in patients treated with 5-FU alone in Group 1[169]. Even lower-grade toxicity can lead to poor treatment compliance[170]. Thus, completing treatment may be more important for deriving the benefits of adjuvant therapy than implementing doublet therapy for particularly vulnerable aged patients with CRC[168]. A nationwide, population-based observational study supports this notion, reporting that completing all cycles of adjuvant FOLFOX or CAPOX therapy was associated with improved CSS, regardless of dose reduction or oxaliplatin discontinuation[171].
There are numerous image-based, objective, and questionnaire-based metrics that can be used to screen for and/or diagnose sarcopenia. Most metrics have sex-specific cut-offs that often differ between Western and Asian populations, as shown in Table 1. Muscle mass and other body components can be evaluated using different methods, including computed tomography (CT), dual-energy X-ray absorptiometry and bioelectrical impedance analysis (BIA). Sarcopenia should be diagnosed not only by loss of skeletal muscle mass, but also by reduced muscle strength and function, reduced physical performance, impaired mobility, and decreased QoL[15,172]. The European Working Group on Sarcopenia in Older People especially recommends assessing muscle quantity and quality rather than muscle mass[15]. According to the latest AWGS criteria, a diagnosis of sarcopenia requires low muscle strength and low muscle mass[172]. Moreover, a salient concept, sarcopenic obesity, has recently emerged. This condition is characterized by an unfavorable combination of low skeletal muscle mass and obesity. Fatty infiltration in skeletal muscle mass is known to have a detrimental impact on muscle functionality and can further exacerbate sarcopenia[173]. It is imperative to acknowledge that the term "sarcopenia" employed in the literature as cited in the following paragraphs may simply indicate a loss of skeletal muscle mass.
| Metrics | Summary | Methodology | Asian/AWGS | Western/EWGSOP | ||
| Cut-off for men | Cut-off for women | Cut-off for men | Cut-off for women | |||
| Calf circumference | Thickest circumference | Tape measure | < 34 cm | < 33 cm | < 34 cm1 | < 33 cm1 |
| SMI | Total skeletal muscle area at L3 divided by squared height | CT | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults |
| PMI | Total psoas muscle area at L3 divided by squared height | CT | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults | ≤ -2 SD of young adults |
| ASMI | Appendicular muscle mass divided by squared height | DXA | < 7.0 kg/m2 (> 65 years) | < 5.4 kg/m2 (> 65 years) | < 7.0 kg/m2 | < 5.5 kg/m2 |
| < 7.2 kg/m2 (for 50-64 years) | < 5.5 kg/m2 (for 50-64 years) | |||||
| ASMI | Appendicular muscle mass divided by squared height | BIA | < 7.0 kg/m2 (for > 65 years) | < 5.7 kg/m2 (for > 50 years) | < 8.50 kg/m2 for severe | < 5.75 kg/m2 for severe |
| < 7.6 kg/m2 (for 50-64 years) | < 10.75 kg/m2 for moderate | < 6.75 kg/m2 for moderate | ||||
| SARC-F | 5 items (muscle strength, assistance with walking, rise from a chair, climb stairs, and falls) | Questionnaire | ≥ 4 points | ≥ 4 points | ≥ 4 points | ≥ 4 points |
| SARC-CalF | SARC-F + calf circumference | Questionnaire, tape measure | ≥ 11 points | ≥ 11 points | ≥ 11 points1 | ≥ 11 points1 |
| Hand grip | Maximum strength in 2-3 trials | Hand dynamometer | < 28 kg (for > 65 years) | < 18 kg (> 65 years) | < 27 kg | < 16 kg |
| < 34 kg (for 50-64 years) | < 20 kg (for 50-64 years) | |||||
| Repeated chair stand test | Total time of 5 rises | ≥ 12 seconds (for > 65 years) | ≥ 12 seconds (for > 65 years) | ≥ 15 seconds | ≥ 15 seconds | |
| ≥ 10 seconds (for 50-64 years) | ≥ 10 seconds (for 50-64 years) | |||||
| Gait speed | Speed in a 4- or 6-m walk | < 1.0 m/second (for > 65 years) | < 1.0 m/second (for > 65 years) | < 0.8 m/second | < 0.8 m/second | |
| < 1.2 m/second (for 50-64 years) | < 1.2 m/second (for 50-64 years) | |||||
| SPPB | Standing balance, gait speed, and chair-stand ability | ≤ 9 points (full score: 12) | ≤ 9 points (full score: 12) | ≤ 8 points (full score: 12) | ≤ 8 points (full score: 12) | |
The prevalence of sarcopenia among patients diagnosed with CRC ranged from 12% to 60%[174-176]. Moreover, a higher prevalence of sarcopenia was observed in aged patients (70-80 years) compared to younger patients (age: < 50 years) in a cohort study of 3262 stage I-III CRC cases[177].
As 5-FU interacts with lean body mass (LBM) due to its high hydrophilicity, sarcopenia increases plasma concentrations of 5-FU[178]. It is important to note that oxaliplatin can also interact with adiposity compartments because of its hydrophobic moieties[179,180]. The distinct pharmacokinetics of oxaliplatin in adipose tissue may lead to a high risk of grade 3 or higher chemotherapy toxicities in patients with low LBM and high total adipose tissue[179]. In contrast, the deleterious effects of chemotherapy, including suboptimal nutritional intake and reduced physical activity, can directly and indirectly result in a decrease in skeletal muscle mass[181].
The initial study to demonstrate the association between low LBM and 5-FU toxicity was reported by Prado et al[182]. They proposed that the 5-FU dose should be normalized to LBM, as opposed to the utilization of body surface area as a metric[182]. This is particularly salient in patients with sarcopenic obesity, as a large body weight can translate to a larger body surface area, resulting in chemotherapy overdosing[173,183]. Ali et al[184] also mentioned the importance of normalizing oxaliplatin doses to LBM to reduce the likelihood of DLT, especially peripheral neuropathy. In contrast, BSA and other body size measures do not predict irinotecan clearance or SN-38 pharmacokinetics[43], suggesting that fixed-dose administration of the drug could be safe.
In patients with mCRC, sarcopenia emerged as an independent factor associated with the development of grade 3-4 toxicity, including nausea/vomiting, anemia, neutropenia, and peripheral neuropathy[185]. In a report by Williams et al[178], an association was identified between an escalation in the dosage of 5-FU per kilogram of LBM and the emergence of grade 3-4 toxicity in mFOLFOX6 with/without bevacizumab for mCRC. A secondary analysis of CAIRO-3 trial investigating the maintenance by capecitabine and bevacizumab vs observation alone after capecitabine and oxaliplatin plus bevacizumab regimen for mCRC, revealed that pretreatment sarcopenia and/or muscle loss during treatment were associated with an increased risk of DLT[186]. Furthermore, the decline in skeletal muscle index (SMI) was associated with shorter time to disease progression and poorer OS among patients enrolled in the CAIRO-3 trial[187]. Several Japanese studies have also described an association between skeletal muscle loss after systemic chemotherapy for mCRC and poor treatment response, the development of adverse events, poor PFS, and poor OS[188,189]. In summary, the presence of baseline sarcopenia, as well as the development of sarcopenia during the early phase of chemotherapy, has the potential to influence treatment response and prognosis.
In the context of other palliative treatments, Chemama et al[190] conducted a study on 97 French patients who underwent tumor cytoreductive surgery combined with hyperthermic intraperitoneal perfusion chemotherapy for mCRC with peritoneal metastasis. The study found that chemotherapy toxicity was more prevalent (57%) in patients with sarcopenia than in those without sarcopenia (26%, P = 0.004); specifically, neutropenia was observed more frequently in the sarcopenic group (36%) compared to the non-sarcopenic group (17%, P = 0.04). Gökyer et al[191] demonstrated a robust correlation between sarcopenia and DLT in Turkish patients with refractory mCRC undergoing regorafenib treatment (odds ratio 15.6, P = 0.01).
A subset of patients who initially presented with unresectable disease have shown a conversion to resectable status after undergoing systemic therapy that integrates key cytotoxic drugs (5-FU, oxaliplatin, and irinotecan) with targeted antibodies[6]; their survival outcomes were better than those of patients treated exclusively with systemic therapy[192]. The available literature on the relationship between sarcopenia and conversion therapy in mCRC is limited. Nozawa et al[193] compared changes in SMI during systemic therapy between cases of conversion to resection vs those of no conversion in mCRC; the mean SMI increased by 9.4% in the conversion group, whereas it decreased by 3.7% in the no conversion group. Moreover, among the conversion group, the increase in SMI during systemic therapy was identified as an independent predictor of favorable OS on multivariate analysis (hazard ratio: 0.25)[193].
There is a paucity of research investigating the relationship between sarcopenia and toxicity during CRT for rectal cancer. According to a recent meta-analysis on CRT for various malignancies including rectal cancer, sarcopenia was found to be associated with an increased risk of adverse events in patients undergoing radiotherapy and/or chemotherapy worldwide[194]. Meanwhile, gastrointestinal toxicities may contribute to suboptimal nutritional status, resulting in weight loss and alterations in body composition during preoperative CRT[195]. A preliminary case study revealed that patients with sarcopenia who underwent TNT for rectal cancer exhibited frequent thrombocytopenia and cystitis[196].
The available data on the relationship between sarcopenia and response to CRT are also limited. A retrospective study of a database of Australian institutions revealed that body mass index < 25 kg/m2, but not sarcopenia, was associated with poor tumor regression grade after CRT[197]. Interestingly, the same group reported that sarcopenia exhibited a negative correlation with tumor response following TNT in patients diagnosed with advanced rectal cancer[198].
Berkel et al[199] reported that sarcopenic obesity was associated with an increased risk of overall surgical complications in patients with rectal cancer who underwent neoadjuvant CRT and surgery. In terms of prognosis, substantial evidence from Western and Asian countries indicates that low skeletal muscle mass, skeletal muscle loss, and a reduced body mass index during preoperative CRT are predictors of poor DFS and/or OS in patients with advanced rectal cancer[195,200-203].
A number of studies have reported frequent adverse events, including neutropenia, neuropathy, and severe diarrhea, in Caucasian and Asian patients with low skeletal muscle mass who received adjuvant chemotherapy[163,204-206]. Among them, the C-SCANS study revealed that patients with low SMA before surgery were associated with DLT, including treatment delay and premature treatment cessation in adjuvant FOLFOX therapy[205]. Shiraishi et al[163] also found that the completion rate of adjuvant monotherapy or doublet therapy was lower in patients with a low psoas muscle index (PMI) (< 524 mm2/m2 for men and < 385 mm2/m2 for women) than the remaining patients. We conducted a longitudinal study on sarcopenia-related indices during adjuvant CAPOX in patients with high-risk stage II or stage III CRC. Our findings, based on BIA, revealed retarded recovery in muscle mass and bone mineral during the treatment in female patients[207], suggesting a connection between disturbed body compositions and women's predisposition to develop intolerance to chemotherapy.
A Korean research group examined the changes in body measurements that occurred during adjuvant FOLFOX chemotherapy in patients with stage III or high-risk stage II colon cancer; they found that visceral fat loss of at least 46.57% and reduction of > 2 Hounsfield units in skeletal muscle radiodensity during adjuvant chemotherapy were associated with poor OS[208]. More recently, the LEANOX trial demonstrated that for sarcopenic patients (LBM index ≥ 3.09 mg/kg) with stage III colon cancer, adjusting the oxaliplatin dose according to LBM is an effective strategy for reducing oxaliplatin-induced peripheral neuropathy and enhancing QoL compared to BSA-based dosage. This adjustment does not impact either RFS or OS in adjuvant settings[209]. These studies used different metrics and specific cut-off values for their own cohorts, which may have led to different results. In summary, whether body compositions affect prognosis after adjuvant chemotherapy remains undetermined.
The associations between adiposity or myosteatosis, as revealed by CT scans, and adherence to adjuvant chemotherapy or subsequent survival have been a subject of ongoing debate[210,211].
The literature offers a variety of definitions for older adults, ranging from 65 years to 75 years of age. Furthermore, the classification of patients as fit, vulnerable, or frail remains unclear, leading to heterogeneous groups of subjects across studies that may potentially impact the results. The efficacy of certain chemotherapeutic drugs, such as 5-FU, appears to be comparable in older and younger patients. In contrast, older adults are more likely to develop significant toxicity. When working with such patients, the question of which geriatric assessment tools should be used to determine the chemotherapy regimen or dose reduction remains unanswered.
A coherent definition and set of cut-offs for sarcopenia and low skeletal muscle mass are not available at this time. Moreover, these thresholds vary across different ethnic groups, as demonstrated in Table 1. Furthermore, numerous studies on skeletal muscle mass-related indices have defined cut-offs using the tertile, quartile, or quintile values of SMI, PMI, or other indices among their respective cohorts. These variations can limit the generalizability of the results. It is important to note that the conclusions of studies conducted in Western countries may not be applied to non-Western patient populations. Given the potential for body composition differences based on race and ethnicity, further studies are needed to explore global applications and customized cut-off values for sarcopenia. In addition to conducting sex- and age-specific evaluations of the pharmacokinetics and pharmacodynamics of chemotherapeutic drugs, we are currently awaiting the development of optimal dosing methods.
Moreover, there are clear distinctions between the backgrounds of patients in the real world and those who met the stringent criteria for clinical research, particularly those for RCTs. Another limitation of the available literature is publication bias. Positive or unexpected findings are more likely to be reported or published. Therefore, the applicability of the findings in the literature to daily practice requires careful re-evaluation.
In the above sections and Table 2, we have outlined the safety and efficacy of various treatments ranging from conventional regimens to recently approved anti-tumor drugs for CRC, with regard to the three S's. We presented the results of the selected literature as the independent effects of the three S's in the treatments after reviewing the analytic methods. However, readers should be aware of the possible confounding effects of these factors in other literature due to their close relationship to previous sections, as mentioned earlier.
| Outcome | Setting | Women (vs men) | Fit, aged (vs younger) | Sarcopenia/reduced skeletal muscle (vs no sarcopenia) |
| Safety | Palliative chemotherapy | Increased gastrointestinal and hematological toxicities (5-FU, oxaliplatin, irinotecan) | Increased diarrhea and neutropenia (5-FU, oxaliplatin, irinotecan) | Increased neurological, gastrointestinal and hematological toxicities |
| Increased nausea (trifluridine/tipiracil) | No difference (trifluridine/tipiracil) | Frequent DLT (5-FU, oxaliplatin) | ||
| No difference (anti-VEGF) | Increased thrombocytopenia (bevacizumab) | Frequent DLT (regorafenib) | ||
| No different toxicity (anti-EGFR) | No different toxicity (fruquintinib) | |||
| Increased fatigue, hypertension, skin toxicity, and anorexia (regorafenib) | Increased diarrhea, frequent body weight loss (aflibercept) | |||
| No different toxicity (T-Dxd) | No different toxicity (regorafenib) | |||
| Severer irAEs (ICIs) | ||||
| Chemoradiotherapy | Frequent interruption and discontinuation | Frequent dose reduction | Probable increased cystitis and thrombocytopenia | |
| Increased diarrhea, perianal dermatitis, and hematological toxicities | No different toxicity | |||
| Adjuvant chemotherapy | Frequent dose reduction (5-FU, oxaliplatin). Decreased completion rate (oxaliplatin) | No different toxicity (5-FU) | Decreased completion rate (oxaliplatin) | |
| Probable increased toxicity (oxaliplatin) | Frequent DLT (oxaliplatin) | |||
| Efficacy | Palliative chemotherapy | Comparable PFS and OS (5-FU, oxaliplatin) | Comparable RR and OS (5-FU) | Poorer PFS and OS (5-FU, oxaliplatin) |
| Comparable PFS and OS (ICIs) | Comparable RR and undermined survival benefit (oxaliplatin, irinotecan) | |||
| Comparable PFS and OS (trifluridine/tipiracil) | ||||
| Comparable PFS and undermined survival benefit (bevacizumab) | ||||
| Comparable OS (ramucirumab, aflibercept, fruquintinib) | ||||
| Comparable RR and PFS (anti-EGFR) | ||||
| Comparable RR and PFS (T-Dxd) | ||||
| No survival benefit (pembrolizumab) | ||||
| Comparable PFS (nivolumab + ipilimumab) | ||||
| Chemoradiotherapy | Comparable tumor regression and pathological response | Comparable tumor regression and pathological response | Undetermined impact on response | |
| Adjuvant chemotherapy | Better DFS, RFS, and OS (5-FU, oxaliplatin) | Comparable survivals (5-FU) | Undetermined survival benefit (5-FU, oxaliplatin) | |
| Undetermined survival benefit (oxaliplatin) |
Based on currently available knowledge, several scenarios can be applied in clinical practice for CRC in patients with overlapping risk factors of the three S's. For instance, using LBM instead of body surface area to adjust chemotherapy doses could minimize side effects while maintaining anti-tumor efficacy in women suspected of having sarcopenic obesity. Screening with tools such as the G-8 is easily performed on all older adults with CRC at the time of initial diagnosis. A geriatric assessment should be implemented prior to any chemotherapy or CRT because modified treatment schedules may benefit older adults in both palliative and adjuvant settings, as mentioned above.
While sex, age, and certain factors, such as those related to CRC, are unchangeable, some lifestyle risk factors associated with sarcopenia can be modified. Therefore, early screening, such as during the initial hospital visit, is the optimal first step in diagnosing sarcopenia based on race-specific criteria. A common approach for the prevention and treatment of sarcopenia in cancer patients is targeted exercise[212]. In addition, nutritional support, including dietary intake, high energy, high protein, omega-3 fatty acids, and anabolic-orexigenic agents can also contribute to muscle mass preservation[173,213]. A recent meta-analysis concluded that nutritional interventions may be an effective strategy for enhancing muscle strength following a 3-month intervention period[213]. In fact, a Korean group reported that four sessions of nutritional counseling before and after the initiation of adjuvant chemotherapy may help to mitigate body weight loss and gastrointestinal symptoms in CRC[214]. The efficacy of other possible intervention methods for sa
Several ongoing prospective trials are investigating the impact of adjustment based on geriatric assessment on the outcomes of cancer treatments in CRC. One RCT (NCT02978612)[215] first employs a CGA to select fit or intermediate patients with stage III colon cancer, and then randomizes them to receive either capecitabine for six months or no adjuvant chemotherapy. The endpoints of this RCT include chemotherapy-induced loss of function, QoL, and survival. The SaVe project comprises three RCTs investigating the effect of CGA plus a group-based exercise intervention on the maintenance of walking balance, lower limb strength, and endurance at 12 weeks in patients aged over 65 years with CRC undergoing palliative, neoadjuvant, or adjuvant chemotherapy[216]. However, studies investigating body com
To conclude, more clinical research focusing on sarcopenia and sex-specific chemotherapy and CRT for CRC is warranted in the near future. Subsequent research endeavors encompassing the aforementioned issues will facilitate a more precise comprehension of the impact of the three S's on cancer treatments for CRC, thereby enhancing patient-oriented care.
| 1. | World Health Organization. Colorectal cancer. Fact sheet. Geneva: WHO; 2026. Feb 13, 2026. [cited 23 October 2026]. Available from: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer. |
| 2. | Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76:e70090. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 93] [Article Influence: 93.0] [Reference Citation Analysis (2)] |
| 3. | Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70067. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 42] [Article Influence: 42.0] [Reference Citation Analysis (2)] |
| 4. | Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, Yoshino T, Taieb J, Martinelli E, Arnold D; ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291-1305. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1145] [Cited by in RCA: 1047] [Article Influence: 174.5] [Reference Citation Analysis (9)] |
| 5. | Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22-iv40. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1481] [Cited by in RCA: 1396] [Article Influence: 155.1] [Reference Citation Analysis (9)] |
| 6. | Kinugasa Y, Uehara K, Yamaguchi K, Saito Y, Murofushi K, Sugai T, Ishiguro M, Ishihara S, Ueno H, Oka S, Kato T, Kanemitsu Y, Kawakami H, Kobayashi H, Sakamoto Y, Shiozawa M, Shiomi A, Shinozaki E, Takiyama H, Taniguchi H, Nakajima TE, Hotta K, Matsuda K, Murata K, Morita S, Yamazaki K, Yoshida M, Yamaguchi N, Kagawa H, Yamauchi S, Ajioka Y; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer. Int J Clin Oncol. 2025;30:2410-2463. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 50] [Reference Citation Analysis (0)] |
| 7. | NCCN Clinical Practice Guidelines in Oncology. Colon Cancer version 2. 2026. [cited 11 October 2026]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. |
| 8. | NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer version 2. 2026. [cited 11 October 2026]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. |
| 9. | André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21:1620-1629. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 165] [Cited by in RCA: 230] [Article Influence: 38.3] [Reference Citation Analysis (2)] |
| 10. | Cremolini C, Chalabi M, Elez E, Fassan M, Gelli M, Goéré D, Modest DP, Montagut C, Osterlund P, Ricke J, Seligmann J, Taieb J, Yoshino T, Wyrwicz L, Ducreux M; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37:759-776. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 40] [Article Influence: 40.0] [Reference Citation Analysis (0)] |
| 11. | Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, Yoshino T. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:444-455. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 62] [Cited by in RCA: 73] [Article Influence: 36.5] [Reference Citation Analysis (3)] |
| 12. | Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-1471. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 630] [Cited by in RCA: 588] [Article Influence: 39.2] [Reference Citation Analysis (14)] |
| 13. | Gomez D, Calderón C, Carmona-Bayonas A, Cacho Lavin D, Muñoz MM, Martinez Cabañez R, Jimenez-Fonseca P. Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clin Transl Oncol. 2021;23:657-662. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 18] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 14. | Bozzetti F. Chemotherapy-Induced Sarcopenia. Curr Treat Options Oncol. 2020;21:7. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 90] [Cited by in RCA: 79] [Article Influence: 13.2] [Reference Citation Analysis (0)] |
| 15. | Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 12211] [Cited by in RCA: 10084] [Article Influence: 1440.6] [Reference Citation Analysis (36)] |
| 16. | Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle. 2011;2:1-3. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 123] [Cited by in RCA: 129] [Article Influence: 8.6] [Reference Citation Analysis (0)] |
| 17. | Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985). 2000;89:81-88. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2427] [Cited by in RCA: 2068] [Article Influence: 79.5] [Reference Citation Analysis (5)] |
| 18. | Cherin P, Voronska E, Fraoucene N, de Jaeger C. Prevalence of sarcopenia among healthy ambulatory subjects: the sarcopenia begins from 45 years. Aging Clin Exp Res. 2014;26:137-146. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 56] [Cited by in RCA: 70] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 19. | Papadopoulou SK, Tsintavis P, Potsaki P, Papandreou D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2020;24:83-90. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 220] [Cited by in RCA: 209] [Article Influence: 34.8] [Reference Citation Analysis (0)] |
| 20. | Gallagher D, Visser M, De Meersman RE, Sepúlveda D, Baumgartner RN, Pierson RN, Harris T, Heymsfield SB. Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J Appl Physiol (1985). 1997;83:229-239. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 682] [Cited by in RCA: 668] [Article Influence: 23.0] [Reference Citation Analysis (0)] |
| 21. | Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK; ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013;14:528.e1-528.e7. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 142] [Cited by in RCA: 184] [Article Influence: 14.2] [Reference Citation Analysis (0)] |
| 22. | Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 424] [Cited by in RCA: 766] [Article Influence: 85.1] [Reference Citation Analysis (1)] |
| 23. | Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, Kolonel LN, Murphy SP, Chang L, Novotny R, Le Marchand L. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2011;1:e6. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 110] [Cited by in RCA: 179] [Article Influence: 11.9] [Reference Citation Analysis (0)] |
| 24. | Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 635] [Cited by in RCA: 979] [Article Influence: 69.9] [Reference Citation Analysis (1)] |
| 25. | Lau EM, Lynn HS, Woo JW, Kwok TC, Melton LJ 3rd. Prevalence of and risk factors for sarcopenia in elderly Chinese men and women. J Gerontol A Biol Sci Med Sci. 2005;60:213-216. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 156] [Cited by in RCA: 182] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
| 26. | Liu LK, Lee WJ, Liu CL, Chen LY, Lin MH, Peng LN, Chen LK. Age-related skeletal muscle mass loss and physical performance in Taiwan: implications to diagnostic strategy of sarcopenia in Asia. Geriatr Gerontol Int. 2013;13:964-971. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 67] [Cited by in RCA: 83] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 27. | Shimokata H, Ando F, Yuki A, Otsuka R. Age-related changes in skeletal muscle mass among community-dwelling Japanese: a 12-year longitudinal study. Geriatr Gerontol Int. 2014;14 Suppl 1:85-92. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 70] [Cited by in RCA: 95] [Article Influence: 7.9] [Reference Citation Analysis (0)] |
| 28. | Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889-896. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2098] [Cited by in RCA: 2237] [Article Influence: 93.2] [Reference Citation Analysis (6)] |
| 29. | Wilkins T, McMechan D, Talukder A. Colorectal Cancer Screening and Prevention. Am Fam Physician. 2018;97:658-665. [PubMed] |
| 30. | Huang P, Liu Y. A Reasonable Diet Promotes Balance of Intestinal Microbiota: Prevention of Precolorectal Cancer. Biomed Res Int. 2019;2019:3405278. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 14] [Cited by in RCA: 46] [Article Influence: 6.6] [Reference Citation Analysis (1)] |
| 31. | Carr PR, Weigl K, Edelmann D, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M. Estimation of Absolute Risk of Colorectal Cancer Based on Healthy Lifestyle, Genetic Risk, and Colonoscopy Status in a Population-Based Study. Gastroenterology. 2020;159:129-138.e9. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 109] [Cited by in RCA: 89] [Article Influence: 14.8] [Reference Citation Analysis (9)] |
| 32. | Choi J, Jia G, Wen W, Shu XO, Zheng W. Healthy lifestyles, genetic modifiers, and colorectal cancer risk: a prospective cohort study in the UK Biobank. Am J Clin Nutr. 2021;113:810-820. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 15] [Cited by in RCA: 59] [Article Influence: 11.8] [Reference Citation Analysis (0)] |
| 33. | Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017;49:10-16. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 396] [Cited by in RCA: 354] [Article Influence: 39.3] [Reference Citation Analysis (0)] |
| 34. | Tsokkou S, Konstantinidis I, Papakonstantinou M, Chatzikomnitsa P, Liampou E, Toutziari E, Giakoustidis D, Bangeas P, Papadopoulos V, Giakoustidis A. Sex Differences in Colorectal Cancer: Epidemiology, Risk Factors, and Clinical Outcomes. J Clin Med. 2025;14:5539. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 27] [Reference Citation Analysis (1)] |
| 35. | Márquez EJ, Chung CH, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, Mellert DJ, Kuchel GA, Banchereau J, Ucar D. Sexual-dimorphism in human immune system aging. Nat Commun. 2020;11:751. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 477] [Cited by in RCA: 456] [Article Influence: 76.0] [Reference Citation Analysis (0)] |
| 36. | Gusella M, Crepaldi G, Barile C, Bononi A, Menon D, Toso S, Scapoli D, Stievano L, Ferrazzi E, Grigoletto F, Ferrari M, Padrini R. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol. 2006;17:1656-1660. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 34] [Cited by in RCA: 45] [Article Influence: 2.3] [Reference Citation Analysis (1)] |
| 37. | Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 2000;18:412-420. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 50] [Cited by in RCA: 55] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
| 38. | Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491-1498. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 109] [Cited by in RCA: 143] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 39. | Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165-1171. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 90] [Cited by in RCA: 113] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
| 40. | Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71:361-370. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 40] [Cited by in RCA: 86] [Article Influence: 6.1] [Reference Citation Analysis (1)] |
| 41. | Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205-1218. [PubMed] |
| 42. | Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002;72:638-647. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 56] [Cited by in RCA: 62] [Article Influence: 2.6] [Reference Citation Analysis (1)] |
| 43. | Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol. 2002;20:81-87. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 53] [Cited by in RCA: 53] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 44. | Heinrich K, Karthaus M, Fruehauf S, Graeven U, Mueller L, König AO, von Weikersthal LF, Caca K, Kretzschmar A, Goekkurt E, Haas S, Alig AHS, Kurreck A, Stahler A, Held S, Sommerhäuser G, Heinemann V, Stintzing S, Trarbach T, Modest DP. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212). ESMO Open. 2023;8:101568. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 9] [Reference Citation Analysis (0)] |
| 45. | Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Corallo S, Morano F, Di Bartolomeo M, Di Maio M, Pietrantonio F. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open. 2021;6:100246. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 11] [Cited by in RCA: 16] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
| 46. | Abdel-Rahman O. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019;18:110-115.e2. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 26] [Cited by in RCA: 33] [Article Influence: 4.1] [Reference Citation Analysis (0)] |
| 47. | Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G, Dell'Aquila E, Ratti M, Bergamo F, Masi G, Urbano F, Ronzoni M, Libertini M, Borelli B, Randon G, Buonadonna A, Allegrini G, Pella N, Ricci V, Boccaccino A, Latiano TP, Cordio S, Passardi A, Tamburini E, Boni L, Falcone A, Cremolini C. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol. 2019;30:1969-1977. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 27] [Cited by in RCA: 32] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
| 48. | Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, Minami H, Sasaki Y. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs. 2001;19:61-67. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 34] [Cited by in RCA: 29] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
| 49. | Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008;34:656-669. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 66] [Cited by in RCA: 71] [Article Influence: 3.9] [Reference Citation Analysis (0)] |
| 50. | Wagner AD, Raeisi M, Rakez M, Diasio RD, Margalit O, Zalcberg JR, Venook AP, Douillard JY, Lenz HJ, Heinemann V, Goldberg RM, van Cutsem E, Schmoll HJ, Shi Q, André T, de Gramont A. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database. Eur J Cancer. 2026;238:116694. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 2] [Article Influence: 2.0] [Reference Citation Analysis (1)] |
| 51. | Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment. J Chemother. 2026;38:169-176. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 52. | Yoshida N, Kuriu Y, Ikeda J, Kudou M, Kirishima T, Okayama T, Miyagawa K, Takagi T, Nakanishi M, Doi T, Ishikawa T, Itoh Y, Otsuji E. Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. Int J Clin Oncol. 2023;28:1378-1387. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 6] [Article Influence: 2.0] [Reference Citation Analysis (1)] |
| 53. | Heinrich K, Stintzing S, Weikersthal LFV, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Jung A, Holch JW, Held S, Modest DP, Heinemann V. Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. Eur J Cancer. 2026;232:116133. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 54. | Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, Henry NL, Fisch MJ, Lee SM, Blanke CD, Hershman DL. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol. 2022;40:1474-1486. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 134] [Cited by in RCA: 252] [Article Influence: 63.0] [Reference Citation Analysis (0)] |
| 55. | Kawakami K, Wakatsuki T, Soejima A, Kobayashi K, Yokokawa T, Aoyama T, Suzuki K, Suenaga M, Yamaguchi K, Inoue A, Machida Y, Hama T. Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer. Patient Prefer Adherence. 2019;13:1745-1750. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 14] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 56. | Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20:326-333. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 57. | Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020;10:688-701. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 114] [Cited by in RCA: 299] [Article Influence: 49.8] [Reference Citation Analysis (0)] |
| 58. | Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14:3332. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 140] [Cited by in RCA: 141] [Article Influence: 47.0] [Reference Citation Analysis (2)] |
| 59. | Nagase M, Houk B, Vuu I, Cardona P, Dutta S, Lin CW. Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRAS(G12C) Mutation from Phase 1 and Phase 2 Studies. AAPS J. 2025;27:26. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 3] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 60. | Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5371] [Cited by in RCA: 4868] [Article Influence: 486.8] [Reference Citation Analysis (9)] |
| 61. | Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5:529-536. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 241] [Cited by in RCA: 236] [Article Influence: 33.7] [Reference Citation Analysis (0)] |
| 62. | Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3:e2012534. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 51] [Cited by in RCA: 99] [Article Influence: 16.5] [Reference Citation Analysis (4)] |
| 63. | Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11:1779. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 204] [Cited by in RCA: 206] [Article Influence: 34.3] [Reference Citation Analysis (2)] |
| 64. | Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF, Becker H, Wittekind C, Sauer R, Rödel C, Liersch T; German Rectal Cancer Study Group. Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol. 2013;108:48-54. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 20] [Cited by in RCA: 34] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
| 65. | Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. JAMA Oncol. 2020;6:294-296. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6] [Cited by in RCA: 14] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 66. | Sapienza LG, Raychaudhuri S, Nahlawi SK, Ozeir S, Abu-Isa E. Predictors of Definitive Treatment Interruptions of Long-Course Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cureus. 2022;14:e30159. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 2] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
| 67. | Lebwohl B, Ballas L, Cao Y, Chan G, Grossman R, Sherr DL, Woodhouse S, Neugut AI. Treatment interruption and discontinuation in radiotherapy for rectal cancer. Cancer Invest. 2010;28:289-294. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 13] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 68. | Yin J, Qureshi MM, Huang D, Truong MT, Mak KS, Yan S, Hirsch AE. Factors Associated With Early Discontinuation of Radiation Therapy: An Analysis of the National Cancer Database. Adv Radiat Oncol. 2025;10:101784. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 69. | Sui X, Shi C, Song M, Jiang W, Li S, Geng J, Xu J, Zhang Y, Zhu X, Cai Y, Li B, Wang H, Dong D, Teng H, Li Y, Wang W. Sex-biased associations between gut microbiota and hematologic toxicity of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Surg. 2026;112:9740-9752. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 70. | Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770-1776. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 415] [Cited by in RCA: 398] [Article Influence: 28.4] [Reference Citation Analysis (9)] |
| 71. | Han YD, Kim WR, Park SW, Cho MS, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Predictors of Pathologic Complete Response in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation. Medicine (Baltimore). 2015;94:e1971. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 21] [Cited by in RCA: 23] [Article Influence: 2.1] [Reference Citation Analysis (1)] |
| 72. | De Felice F, Izzo L, Musio D, Magnante AL, Bulzonetti N, Pugliese F, Izzo P, Di Cello P, Lucchetti P, Izzo S, Tombolini V. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget. 2016;7:33374-33380. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 36] [Cited by in RCA: 37] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 73. | Lutsyk M, Awawda M, Gourevich K, Ben Yosef R. Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Am J Clin Oncol. 2021;44:482-486. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 14] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 74. | Smajlbegović V, Ramić S, Kirac I, Solak Mekić M, Ćurt L, Vrdoljak DV. Tumor Response To Neoadjuvant Long-Course Chemoradiotherapy Depends On The Rectal Cancer Patient Gender. Acta Clin Croat. 2024;63:523-532. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 75. | Cadili L, Loree JM, Peacock M, DeVries K, Ghuman A, Karimuddin AA, Phang PT, Raval MJ, Brown CJ. Pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer in a real-world setting: a population-based study. Front Oncol. 2025;15:1573819. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 76. | Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, Qin LX, Gollub MJ, Wu AJ, Lee M, Patil S, Hezel AF, Marcet JE, Cataldo PA, Polite BN, Herzig DO, Liska D, Oommen S, Friel CM, Ternent CA, Coveler AL, Hunt SR, Garcia-Aguilar J; OPRA Consortium. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2350903. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 109] [Cited by in RCA: 110] [Article Influence: 55.0] [Reference Citation Analysis (1)] |
| 77. | Lin Y. A prognostic nomogram for stage II/III rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgical resection. BMC Surg. 2022;22:256. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 78. | Bong JW, Ju Y, Seo J, Lee JA, Kang SH, Lee SI, Min BW. Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea. Ann Surg Treat Res. 2021;100:282-290. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 79. | Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, Chambers CR, Sawyer MB. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract. 2016;22:454-460. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 14] [Cited by in RCA: 23] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
| 80. | Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. J Natl Cancer Inst. 2021;113:400-407. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 20] [Cited by in RCA: 74] [Article Influence: 12.3] [Reference Citation Analysis (0)] |
| 81. | Nozawa H, Kawai K, Sasaki K, Murono K, Emoto S, Yokoyama Y, Abe S, Kishikawa J, Nagai Y, Sonoda H, Anzai H, Ozawa T, Ishihara S. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. Int J Clin Pract. 2021;75:e14863. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 7] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
| 82. | Hirano H, Kataoka K, Yamaguchi T, Wagner AD, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Mizusawa J, Sano Y, Shiomi A, Shiozawa M, Ohue M, Adachi T, Ueno H, Ikeda S, Komori K, Tsukamoto S, Takashima A, Kanemitsu Y. Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A). Eur J Cancer. 2025;214:115139. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 7] [Reference Citation Analysis (0)] |
| 83. | Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, Shergill AP, Ma C, Couture F, Kuebler JP, Kumar P, Tan B, Krishnamurthi SS, Ng K, O'Reilly EM, Brown JC, Meyerhardt JA. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025;117:2643-2652. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 7] [Article Influence: 7.0] [Reference Citation Analysis (2)] |
| 84. | Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457-3465. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1587] [Cited by in RCA: 1398] [Article Influence: 93.2] [Reference Citation Analysis (1)] |
| 85. | Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, Molina-Garrido MJ. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131:16-23. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 19] [Cited by in RCA: 34] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
| 86. | Shafiei M, Yoon R, McLachlan A, Boddy A, Beale P, Blinman P. Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. Ther Drug Monit. 2019;41:553-560. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 5] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 87. | Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-2134. [PubMed] |
| 88. | Devons CA. Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care. 2002;5:19-24. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 78] [Cited by in RCA: 75] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
| 89. | Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K, Flamaing J, Lobelle JP, Wildiers H. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32:19-26. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 237] [Cited by in RCA: 281] [Article Influence: 21.6] [Reference Citation Analysis (0)] |
| 90. | Liuu E, Canouï-Poitrine F, Tournigand C, Laurent M, Caillet P, Le Thuaut A, Vincent H, Culine S, Audureau E, Bastuji-Garin S, Paillaud E; ELCAPA Study Group. Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol. 2014;5:11-19. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 49] [Cited by in RCA: 58] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
| 91. | Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol. 2015;26:288-300. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 648] [Cited by in RCA: 579] [Article Influence: 52.6] [Reference Citation Analysis (11)] |
| 92. | Gajra A, Klepin HD, Feng T, Tew WP, Mohile SG, Owusu C, Gross CP, Lichtman SM, Wildes TM, Chapman AE, Dotan E, Katheria V, Zavala L, Akiba C, Hurria A; Cancer and Aging Research Group (CARG). Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. J Geriatr Oncol. 2015;6:133-140. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 45] [Cited by in RCA: 55] [Article Influence: 5.0] [Reference Citation Analysis (2)] |
| 93. | Feliu J, Espinosa E, Basterretxea L, Paredero I, Llabrés E, Jiménez-Munárriz B, Antonio-Rebollo M, Losada B, Pinto A, Gironés R, Custodio AB, Muñoz MDM, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, Molina-Garrido MJ. Undertreatment and overtreatment in older patients treated with chemotherapy. J Geriatr Oncol. 2021;12:381-387. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 27] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 94. | Li D, Sun CL, Kim H, Soto-Perez-de-Celis E, Chung V, Koczywas M, Fakih M, Chao J, Cabrera Chien L, Charles K, Hughes SFDS, Katheria V, Trent M, Roberts E, Jayani R, Moreno J, Kelly C, Sedrak MS, Dale W. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7:e214158. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 65] [Cited by in RCA: 395] [Article Influence: 79.0] [Reference Citation Analysis (1)] |
| 95. | Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, Flannery MA, Obrecht S, Gilmore N, Ramsdale E, Dunne RF, Wildes T, Plumb S, Patil A, Wells M, Lowenstein L, Janelsins M, Mustian K, Hopkins JO, Berenberg J, Anthony N, Dale W. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398:1894-1904. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 216] [Cited by in RCA: 485] [Article Influence: 97.0] [Reference Citation Analysis (0)] |
| 96. | Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463-476. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 373] [Cited by in RCA: 329] [Article Influence: 29.9] [Reference Citation Analysis (3)] |
| 97. | Feliu J, Escudero P, Llosa F, Bolaños M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gómez L, Casado E, Gómez-Reina MJ, González-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005;23:3104-3111. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 102] [Cited by in RCA: 93] [Article Influence: 4.4] [Reference Citation Analysis (6)] |
| 98. | Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ, Blanke CD. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer. 2013;109:1744-1749. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 11] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 99. | Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-4091. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 385] [Cited by in RCA: 332] [Article Influence: 16.6] [Reference Citation Analysis (2)] |
| 100. | Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443-1451. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 195] [Cited by in RCA: 167] [Article Influence: 9.3] [Reference Citation Analysis (3)] |
| 101. | Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-1759. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 355] [Cited by in RCA: 327] [Article Influence: 21.8] [Reference Citation Analysis (4)] |
| 102. | Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provençal J, Breysacher G, Legoux JL, Lepère C, Charneau J, Cretin J, Chone L, Azzedine A, Bouché O, Sobhani I, Bedenne L, Mitry E; FFCD investigators. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016;27:121-127. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 76] [Cited by in RCA: 75] [Article Influence: 7.5] [Reference Citation Analysis (0)] |
| 103. | Landre T, Uzzan B, Nicolas P, Aparicio T, Zelek L, Mary F, Taleb C, Des Guetz G. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Int J Colorectal Dis. 2015;30:1305-1310. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 24] [Cited by in RCA: 24] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 104. | Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 717] [Cited by in RCA: 642] [Article Influence: 30.6] [Reference Citation Analysis (0)] |
| 105. | Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP; AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077-1085. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 544] [Cited by in RCA: 487] [Article Influence: 37.5] [Reference Citation Analysis (10)] |
| 106. | Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018;29:133-138. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 41] [Cited by in RCA: 57] [Article Influence: 8.1] [Reference Citation Analysis (0)] |
| 107. | Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD, Zelek L, Aparicio T. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis. 2018;33:1125-1130. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 15] [Cited by in RCA: 16] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 108. | Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78:329-339. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 110] [Cited by in RCA: 98] [Article Influence: 6.1] [Reference Citation Analysis (2)] |
| 109. | Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136:737-743. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 132] [Cited by in RCA: 114] [Article Influence: 7.1] [Reference Citation Analysis (2)] |
| 110. | Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499-508. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 805] [Cited by in RCA: 709] [Article Influence: 64.5] [Reference Citation Analysis (13)] |
| 111. | Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018;9:32-39. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 34] [Cited by in RCA: 33] [Article Influence: 4.1] [Reference Citation Analysis (1)] |
| 112. | Li J, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Xu R, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Xu J, Chen D, Li W, Sun S, Yu Z, Cao P, Shen L, Chen H, Wang S, Wang H, Fan S, Guo X, Wang N, Han R, Zhang B, Qin S. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Adv Ther. 2020;37:4585-4598. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 21] [Article Influence: 3.5] [Reference Citation Analysis (2)] |
| 113. | Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402:41-53. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 289] [Cited by in RCA: 288] [Article Influence: 96.0] [Reference Citation Analysis (0)] |
| 114. | Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 2012;10:213-224; quiz 225. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 35] [Cited by in RCA: 47] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
| 115. | Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer. 2022;163:1-15. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6] [Cited by in RCA: 13] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 116. | Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, Chang DY, Macpherson E, Qin A, Singh J, Taitt C, Shire N, Camidge DR. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7:100554. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 228] [Article Influence: 57.0] [Reference Citation Analysis (0)] |
| 117. | Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2019;4:376-388. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 26] [Cited by in RCA: 60] [Article Influence: 8.6] [Reference Citation Analysis (0)] |
| 118. | Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer. 2018;18:98. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 15] [Cited by in RCA: 15] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 119. | Méndez Méndez JC, Salgado Fernández M, de la Cámara Gómez J, Pellón Augusto ML, Covela Rua M, Quintero Aldana G, Fernández Montes A, Reboredo López M, Valladares Ayerbes M, Jorge Fernández M, González Villarroel P, Romero Reinoso C, Ramos Vázquez M; Galician Research Group on Digestive Tumours (GITuD). First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study. J Geriatr Oncol. 2020;11:1263-1267. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 9] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
| 120. | Terazawa T, Kato T, Goto M, Ohta K, Noura S, Satake H, Kagawa Y, Kawakami H, Hasegawa H, Yanagihara K, Shingai T, Nakata K, Kotaka M, Hiraki M, Konishi K, Nakae S, Sakai D, Kurokawa Y, Shimokawa T, Satoh T. Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602. Oncologist. 2021;26:17-e47. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 9] [Cited by in RCA: 17] [Article Influence: 3.4] [Reference Citation Analysis (1)] |
| 121. | Rosati G, Corsi D, Avallone A, Brugnatelli S, Dell'Aquila E, Cinausero M, Aprile G, Cicero G, Carlomagno C, Colombo A, Rapisardi S, Pinto C, Reggiardo G, Bilancia D. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. J Geriatr Oncol. 2022;13:302-307. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (1)] |
| 122. | Lund CM, Nielsen DL, Schultz M, Dolin TG. Physical decline, falls, and hospitalization among vulnerable older patients in the trajectory of colorectal cancer treatment. J Geriatr Oncol. 2024;15:101820. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 123. | Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63-72. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 44] [Cited by in RCA: 72] [Article Influence: 8.0] [Reference Citation Analysis (2)] |
| 124. | Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018;82:961-969. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 14] [Cited by in RCA: 20] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
| 125. | Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-312. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2394] [Cited by in RCA: 2274] [Article Influence: 174.9] [Reference Citation Analysis (14)] |
| 126. | Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019;24:185-192. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 70] [Cited by in RCA: 104] [Article Influence: 14.9] [Reference Citation Analysis (1)] |
| 127. | André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zuo Y, Fogelman D, Adelberg D, Diaz LA. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277-284. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 106] [Cited by in RCA: 114] [Article Influence: 114.0] [Reference Citation Analysis (11)] |
| 128. | André T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, Garcia-Carbonero R, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383-395. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 138] [Cited by in RCA: 182] [Article Influence: 182.0] [Reference Citation Analysis (0)] |
| 129. | Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5022] [Cited by in RCA: 4432] [Article Influence: 201.5] [Reference Citation Analysis (14)] |
| 130. | Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2274] [Cited by in RCA: 2031] [Article Influence: 101.6] [Reference Citation Analysis (50)] |
| 131. | Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-4625. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1420] [Cited by in RCA: 1262] [Article Influence: 63.1] [Reference Citation Analysis (1)] |
| 132. | Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81:e735-e741. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 52] [Cited by in RCA: 51] [Article Influence: 3.4] [Reference Citation Analysis (4)] |
| 133. | Cai X, Wu H, Peng J, Zhu J, Cai S, Cai G, Zhang Z. Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. Radiat Oncol. 2013;8:86. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 30] [Cited by in RCA: 37] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 134. | Guimas V, Boustani J, Schipman B, Lescut N, Puyraveau M, Bosset JF, Servagi-Vernat S. Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results. Drugs Aging. 2016;33:419-425. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 11] [Cited by in RCA: 16] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 135. | Tougeron D, Roullet B, Paillot B, Hamidou H, Tourani JM, Bensadoun RJ, Michel P, Silvain C. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Dig Liver Dis. 2012;44:350-354. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 28] [Cited by in RCA: 28] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 136. | De Felice F, Llange K, Rubini F, Bulzonetti N, Caiazzo R, Musio D, Tombolini V. Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes. Clin Colorectal Cancer. 2018;17:e77-e81. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 9] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 137. | Tominaga T, Nagasaki T, Akiyoshi T, Fukunaga Y, Fujimoto Y, Yamaguchi T, Konishi T, Nagayama S, Ueno M. Feasibility of neoadjuvant therapy for elderly patients with locally advanced rectal cancer. Surg Today. 2019;49:694-703. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 5] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 138. | Otowa Y, Matsuda T, Ando M, Hasegawa H, Koterazawa Y, Sugita Y, Ikeda T, Aoki T, Harada H, Urakawa N, Goto H, Kanaji S, Kakeji Y. Chronological age does not predict poor outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a retrospective study. Surg Today. 2026;56:2061-2067. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 139. | Liu H, Li C, Zhao Z, Guan X, Yang M, Liu Z, Tang Y, Jiang Z, Wang X. Safety and Long-Term Effect Assessment of Neoadjuvant Chemoradiotherapy for Elderly Patients With Locally Advanced Rectal Cancer: A CHN Single-Center Retrospective Study. Technol Cancer Res Treat. 2020;19:1533033820970339. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 5] [Article Influence: 0.8] [Reference Citation Analysis (1)] |
| 140. | François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, Magné N. Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial. Eur J Cancer. 2023;180:62-70. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 19] [Reference Citation Analysis (0)] |
| 141. | Fleischmann M, Diefenhardt M, Trommel M, Scherf C, Ramm U, Chatzikonstantinou G, Fokas E, Rödel C, Tselis N. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. Strahlenther Onkol. 2022;198:654-662. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 12] [Reference Citation Analysis (0)] |
| 142. | Gerard JP, Barbet N, Schiappa R, Magné N, Martel I, Mineur L, Deberne M, Zilli T, Dhadda A, Myint AS; ICONE group. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8:356-367. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 146] [Article Influence: 48.7] [Reference Citation Analysis (1)] |
| 143. | Stewart AJ, Van Limbergen EJ, Gerard JP, Appelt AL, Verhaegen F, Berbee M, Vuong T, Brooker C, Rockall T, Sun Myint A. GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. Clin Transl Radiat Oncol. 2022;33:15-22. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 18] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 144. | Bananzadeh A, Hafezi AA, Nguyen N, Omidvari S, Mosalaei A, Ahmadloo N, Ansari M, Mohammadianpanah M. Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients. Radiat Oncol J. 2021;39:270-278. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 4] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 145. | Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VEPP, Rutten HJT, van den Brule AJC. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21:2396-2402. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 214] [Cited by in RCA: 206] [Article Influence: 12.9] [Reference Citation Analysis (1)] |
| 146. | Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69-77. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1094] [Cited by in RCA: 968] [Article Influence: 37.2] [Reference Citation Analysis (12)] |
| 147. | Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-618. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1480] [Cited by in RCA: 1348] [Article Influence: 64.2] [Reference Citation Analysis (18)] |
| 148. | Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1771] [Cited by in RCA: 1633] [Article Influence: 71.0] [Reference Citation Analysis (6)] |
| 149. | Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126:394-401. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 379] [Cited by in RCA: 337] [Article Influence: 15.3] [Reference Citation Analysis (5)] |
| 150. | Antonio M, Saldaña J, Carmona-Bayonas A, Navarro V, Tebé C, Nadal M, Formiga F, Salazar R, Borràs JM. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making? Oncologist. 2017;22:934-943. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 31] [Cited by in RCA: 48] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
| 151. | Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190-1197. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 137] [Cited by in RCA: 120] [Article Influence: 8.6] [Reference Citation Analysis (1)] |
| 152. | Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, Ohue M, Kato T, Takii Y, Sato T, Tomita N, Yamaguchi S, Akaike M, Mishima H, Kubo Y, Nakamura K, Fukuda H, Moriya Y. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50:2231-2240. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 80] [Cited by in RCA: 98] [Article Influence: 8.2] [Reference Citation Analysis (2)] |
| 153. | Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki H, Takii Y, Mochizuki H, Kotake K, Kameoka S, Takahashi K, Watanabe T, Watanabe M, Boku N, Tomita N, Nakatani E, Sugihara K; ACTS-CC study group. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;25:1743-1749. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 85] [Cited by in RCA: 88] [Article Influence: 7.3] [Reference Citation Analysis (5)] |
| 154. | Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-2029. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1072] [Cited by in RCA: 976] [Article Influence: 51.4] [Reference Citation Analysis (5)] |
| 155. | André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3029] [Cited by in RCA: 2737] [Article Influence: 124.4] [Reference Citation Analysis (10)] |
| 156. | Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768-3774. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 538] [Cited by in RCA: 497] [Article Influence: 33.1] [Reference Citation Analysis (4)] |
| 157. | Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review. Clin Oncol (R Coll Radiol). 2017;29:459-465. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 90] [Cited by in RCA: 89] [Article Influence: 9.9] [Reference Citation Analysis (4)] |
| 158. | Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26:715-724. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 99] [Cited by in RCA: 95] [Article Influence: 8.6] [Reference Citation Analysis (0)] |
| 159. | McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013;31:2600-2606. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 199] [Cited by in RCA: 191] [Article Influence: 14.7] [Reference Citation Analysis (3)] |
| 160. | Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020;31:480-486. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 22] [Cited by in RCA: 28] [Article Influence: 4.7] [Reference Citation Analysis (0)] |
| 161. | Kawamura H, Morishima T, Sato A, Honda M, Miyashiro I. Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study. BMC Cancer. 2020;20:19. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 14] [Cited by in RCA: 27] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 162. | Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624-2634. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 203] [Cited by in RCA: 190] [Article Influence: 13.6] [Reference Citation Analysis (2)] |
| 163. | Shiraishi T, Ogawa H, Shioi I, Ozawa N, Osone K, Okada T, Sohda M, Shirabe K, Saeki H. Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non-elderly patients in stage III colorectal cancer. Ann Gastroenterol Surg. 2023;7:91-101. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6] [Cited by in RCA: 11] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 164. | Yamano T, Yamauchi S, Kimura K, Babaya A, Hamanaka M, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Tomita N, Sugihara K; Japanese Study Group for Postoperative Follow-up of Colorectal Cancer. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. Eur J Cancer. 2017;81:90-101. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 33] [Cited by in RCA: 48] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
| 165. | Okamoto K, Nozawa H, Emoto S, Murono K, Sasaki K, Ishihara S. Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan. J Chemother. 2024;36:319-328. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 166. | Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer. 2002;94:1931-1938. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 49] [Cited by in RCA: 53] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 167. | Lund CM, Nielsen D, Dehlendorff C, Christiansen AB, Rønholt F, Johansen JS, Vistisen KK. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1:e000087. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 17] [Cited by in RCA: 32] [Article Influence: 3.2] [Reference Citation Analysis (1)] |
| 168. | van Erning FN, Razenberg LG, Lemmens VE, Creemers GJ, Pruijt JF, Maas HA, Janssen-Heijnen ML. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. Eur J Cancer. 2016;61:1-10. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 10] [Cited by in RCA: 21] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
| 169. | Aparicio T, Bouché O, Etienne PL, Barbier E, Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V, Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M, Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van den Eynde M, Carola E, Hiret S. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial. Dig Liver Dis. 2023;55:541-548. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 18] [Reference Citation Analysis (0)] |
| 170. | Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey N, Ross P, Wang Y, Harari D. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer. 2014;111:2224-2228. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 38] [Cited by in RCA: 57] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
| 171. | Boyle JM, Kuryba A, Cowling TE, van der Meulen J, Fearnhead NS, Walker K, Braun MS, Aggarwal A. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study. Int J Cancer. 2022;150:335-346. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 16] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
| 172. | Chen LK, Hsiao FY, Akishita M, Assantachai P, Lee WJ, Lim WS, Muangpaisan W, Kim M, Merchant RA, Peng LN, Tan MP, Won CW, Yamada M, Woo J, Arai H. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nat Aging. 2025;5:2164-2175. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 193] [Cited by in RCA: 182] [Article Influence: 182.0] [Reference Citation Analysis (0)] |
| 173. | Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases. 2020;8:1188-1202. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 133] [Cited by in RCA: 120] [Article Influence: 20.0] [Reference Citation Analysis (6)] |
| 174. | Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH, Wolfgang CL, Schulick RD, Choti MA, Kamel I, Pawlik TM. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13:439-446. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 340] [Cited by in RCA: 339] [Article Influence: 22.6] [Reference Citation Analysis (3)] |
| 175. | Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107:931-936. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 691] [Cited by in RCA: 640] [Article Influence: 45.7] [Reference Citation Analysis (10)] |
| 176. | Huang DD, Wang SL, Zhuang CL, Zheng BS, Lu JX, Chen FF, Zhou CJ, Shen X, Yu Z. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis. 2015;17:O256-O264. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 206] [Cited by in RCA: 197] [Article Influence: 17.9] [Reference Citation Analysis (9)] |
| 177. | Xiao J, Caan BJ, Cespedes Feliciano EM, Meyerhardt JA, Kroenke CH, Baracos VE, Weltzien E, Kwan ML, Alexeeff SE, Castillo AL, Prado CM. The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. Am J Clin Nutr. 2019;109:615-625. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 71] [Cited by in RCA: 59] [Article Influence: 8.4] [Reference Citation Analysis (0)] |
| 178. | Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol. 2018;81:413-417. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 21] [Cited by in RCA: 40] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 179. | Purcell SA, Kok DE, Ketterl T, Garcia MB, Joffe L, Brown JC, Dieli-Conwright CM, Williams GR. Pharmacokinetics of cancer therapeutics and energy balance: the role of diet intake, energy expenditure, and body composition. J Natl Cancer Inst Monogr. 2023;2023:3-11. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 18] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 180. | Mehmood RK. Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol Rev. 2014;8:256. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 38] [Cited by in RCA: 53] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 181. | Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8:86-101. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 148] [Cited by in RCA: 131] [Article Influence: 18.7] [Reference Citation Analysis (3)] |
| 182. | Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 395] [Cited by in RCA: 482] [Article Influence: 25.4] [Reference Citation Analysis (7)] |
| 183. | Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018;29:ii1-ii9. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 307] [Cited by in RCA: 294] [Article Influence: 36.8] [Reference Citation Analysis (1)] |
| 184. | Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5:607-616. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 87] [Cited by in RCA: 144] [Article Influence: 14.4] [Reference Citation Analysis (0)] |
| 185. | Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583-589. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 160] [Cited by in RCA: 203] [Article Influence: 16.9] [Reference Citation Analysis (4)] |
| 186. | Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, Creemers GJ, Erdkamp F, de Jongh F, Kint P, Simkens L, Tanis B, Tjin-A-Ton M, Van Der Velden A, Punt C, Koopman M, May A. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019;10:803-813. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 65] [Cited by in RCA: 91] [Article Influence: 13.0] [Reference Citation Analysis (7)] |
| 187. | Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Creemers GM, Erdkamp FLG, de Jongh FE, Kint PAM, Poppema BJ, Radema SA, Simkens LHJ, Tanis BC, Tjin-A-Ton MLR, Van Der Velden A, Punt CJA, Koopman M, May AM. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. Cancer Med. 2020;9:1033-1043. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 23] [Cited by in RCA: 29] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
| 188. | Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, Kudo K, Tsuda Y, Nakashima Y, Ando K, Akagi Y, Kakeji Y, Baba H, Maehara Y. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). Int J Clin Oncol. 2019;24:1204-1213. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 21] [Cited by in RCA: 32] [Article Influence: 4.6] [Reference Citation Analysis (1)] |
| 189. | Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Watanabe M, Baba H. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS One. 2015;10:e0129742. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 127] [Cited by in RCA: 121] [Article Influence: 11.0] [Reference Citation Analysis (7)] |
| 190. | Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goéré D, Elias D, Raynard B, Antoun S. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. Ann Surg Oncol. 2016;23:3891-3898. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 47] [Cited by in RCA: 64] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 191. | Gökyer A, Küçükarda A, Köstek O, Hacıoğlu MB, Sunal BS, Demircan NC, Uzunoğlu S, Solak S, İşsever K, Çiçin I, Erdoğan B. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib. Clin Transl Oncol. 2019;21:1518-1523. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 13] [Cited by in RCA: 20] [Article Influence: 2.9] [Reference Citation Analysis (2)] |
| 192. | Chrabaszcz S, Rajeev R, Witmer HDD, Dhiman A, Klooster B, Gamblin TC, Banerjee A, Johnston FM, Turaga KK. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. Am J Clin Oncol. 2022;45:366-372. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 8] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 193. | Nozawa H, Emoto S, Murono K, Shuno Y, Kawai K, Sasaki K, Sonoda H, Ishii H, Iida Y, Yokoyama Y, Anzai H, Ishihara S. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. Ther Adv Gastroenterol. 2020;13:1756284820971197. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 7] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
| 194. | Zhang Y, Zhang J, Zhan Y, Pan Z, Liu Q, Yuan W. Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients With Tumour: A Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle. 2024;15:2295-2310. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 28] [Reference Citation Analysis (1)] |
| 195. | Lin J, Peng J, Qdaisat A, Li L, Chen G, Lu Z, Wu X, Gao Y, Zeng Z, Ding P, Pan Z. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. J Cancer Res Clin Oncol. 2016;142:2551-2560. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 20] [Cited by in RCA: 37] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 196. | Curcean S, Gherman A, Tipcu A, Fekete Z, Muntean AS, Curcean A, Craciun R, Stanciu S, Irimie A. Impact of Sarcopenia on Treatment Outcomes and Toxicity in Locally Advanced Rectal Cancer. Medicina (Kaunas). 2024;60:1606. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 197. | Bedrikovetski S, Traeger L, Price TJ, Carruthers S, Selva-Nayagam S, Moore JW, Sammour T. Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study. J Surg Oncol. 2023;128:75-84. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 18] [Reference Citation Analysis (1)] |
| 198. | Bedrikovetski S, Traeger L, Vather R, Sammour T, Moore JW. Does Sarcopenia Predict Local Response Rates After Chemoradiotherapy for Locally Advanced Rectal Cancer? Dis Colon Rectum. 2023;66:965-972. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 10] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 199. | Berkel AEM, Klaase JM, de Graaff F, Brusse-Keizer MGJ, Bongers BC, van Meeteren NLU. Patient's Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer. Dig Surg. 2019;36:376-383. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 39] [Cited by in RCA: 35] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 200. | Takeda Y, Akiyoshi T, Matsueda K, Fukuoka H, Ogura A, Miki H, Hiyoshi Y, Nagasaki T, Konishi T, Fujimoto Y, Fukunaga Y, Ueno M. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS One. 2018;13:e0195406. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 65] [Cited by in RCA: 64] [Article Influence: 8.0] [Reference Citation Analysis (1)] |
| 201. | Horie K, Matsuda T, Yamashita K, Hasegawa H, Utsumi M, Urakawa N, Kanaji S, Oshikiri T, Kakeji Y. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery. Eur J Surg Oncol. 2022;48:850-856. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 19] [Reference Citation Analysis (0)] |
| 202. | Levolger S, van Vledder MG, Alberda WJ, Verhoef C, de Bruin RWF, IJzermans JNM, Burger JW. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma. Clin Nutr. 2018;37:1728-1735. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 36] [Cited by in RCA: 35] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 203. | Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. Clin Nutr. 2020;39:820-828. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 50] [Cited by in RCA: 48] [Article Influence: 8.0] [Reference Citation Analysis (1)] |
| 204. | Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015;23:687-694. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 135] [Cited by in RCA: 171] [Article Influence: 14.3] [Reference Citation Analysis (1)] |
| 205. | Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, Xiao J, Castillo AL, Caan BJ. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer. 2017;123:4868-4877. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 50] [Cited by in RCA: 93] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
| 206. | Looijaard SMLM, Meskers CGM, Slee-Valentijn MS, Bouman DE, Wymenga ANM, Klaase JM, Maier AB. Computed Tomography-Based Body Composition Is Not Consistently Associated with Outcome in Older Patients with Colorectal Cancer. Oncologist. 2020;25:e492-e501. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 5] [Cited by in RCA: 27] [Article Influence: 3.9] [Reference Citation Analysis (1)] |
| 207. | Nozawa H, Abe S, Abe K, Yokota Y, Hori S, Yakabe M, Sasaki K, Emoto S, Yokoyama Y, Sonoda H, Murono K, Matsuzaki H, Nagai Y, Shinagawa T, Akishita M, Ishihara S. Sex differences in recovery from postoperative sarcopenia during adjuvant CAPOX therapy for colorectal cancer. J Cancer Res Clin Oncol. 2024;150:478. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 208. | Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. Cancers (Basel). 2019;12:60. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 26] [Cited by in RCA: 34] [Article Influence: 4.9] [Reference Citation Analysis (0)] |
| 209. | Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, Galais MP, Janiszewski C, Mazard T, Rinaldi Y, Lepage C, Tetreau R, Senesse P. Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. J Clin Oncol. 2025;43:2616-2627. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 15] [Cited by in RCA: 18] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
| 210. | Lee CS, Murphy DJ, McMahon C, Nolan B, Cullen G, Mulcahy H, Sheahan K, Barnes E, Fennelly D, Ryan EJ, Doherty GA. Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy. J Gastrointest Cancer. 2015;46:243-250. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 49] [Cited by in RCA: 50] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 211. | Brown JC, Meyerhardt JA, Cespedes Feliciano EM, Cheng E, Caan BJ. The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer. Clin Nutr. 2022;41:1600-1604. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 13] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 212. | Derksen JWG, Kurk SA, Oskam MJ, Peeters PHM, Punt CJA, Koopman M, May AM. Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. JNCI Cancer Spectr. 2019;3:pkz014. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 16] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 213. | Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H. Interventions for Treating Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J Am Med Dir Assoc. 2017;18:553.e1-553.e16. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 192] [Cited by in RCA: 289] [Article Influence: 36.1] [Reference Citation Analysis (4)] |
| 214. | Son J, Kang HI, Jung EY, Ryu HW, Lee KH. Effects of Continuous Nutrition Care on Nutritional Status and Dietary Habits of Patients With Colorectal Cancer Receiving Adjuvant Chemotherapy After Surgery. Clin Nutr Res. 2023;12:99-115. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 215. | Guren MG. Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III (ACE). [accessed 2026 Sep 13]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT02978612. |
| 216. | Piper KS, Suetta C, Schou JV, Ryg J, Andersen HE, Langevad LV, Evering D, Mikkelsen MK, Lund C, Christensen J. The SaVe project - Sarcopenia and Vertigo in aging patients with colorectal cancer: A study protocol for three randomized controlled trials. J Geriatr Oncol. 2024;15:101770. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |